Granules India Ltd vs Haleos Labs Limited Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Granules India Ltd is ₹ 699.25 as of 30 Apr 15:30 . The P/E Ratio of Granules India Ltd changed from 13.7 on March 2021 to 23.5 on March 2025 . This represents a CAGR of 11.40% over 5 yearsThe P/E Ratio of Haleos Labs Limited changed from 11 on March 2021 to 16.2 on March 2025 . This represents a CAGR of 8.05% over 5 years The Market Cap of Granules India Ltd changed from ₹ 7511 crore on March 2021 to ₹ 11814 crore on March 2025 . This represents a CAGR of 9.48% over 5 yearsThe Market Cap of Haleos Labs Limited changed from ₹ 149.61 crore on March 2021 to ₹ 326.64 crore on March 2025 . This represents a CAGR of 16.90% over 5 years The revenue of Granules India Ltd for the Mar '26 is ₹ 1495 crore as compare to the Dec '25 revenue of ₹ 1384 crore. This represent the growth of 8.02% The revenue of Haleos Labs Limited for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 94.97 crore. This represent the decline of -100% The ebitda of Granules India Ltd for the Mar '26 is ₹ 376.79 crore as compare to the Dec '25 ebitda of ₹ 304.46 crore. This represent the growth of 23.76% The ebitda of Haleos Labs Limited for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 14.23 crore. This represent the decline of -100% The net profit of Granules India Ltd changed from ₹ 134.65 crore to ₹ 201.57 crore over 8 quarters. This represents a CAGR of 22.35% The net profit of Haleos Labs Limited changed from ₹ 7.1 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Granules India Ltd changed from 6.72 % on March 2021 to 11.39 % on March 2025 . This represents a CAGR of 11.13% over 5 yearsThe Dividend Payout of Haleos Labs Limited changed from 3.44 % on March 2021 to 2.12 % on March 2025 . This represents a CAGR of -9.23% over 5 years .

About Granules India Ltd

Granules India Limited is a large-scale vertically integrated company founded in March, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies. Granules Life Sciences Private Limited, based in Hyderabad, Telangana, is a wholly owned subsidiary of Granules India.
It significantly enhances the Company's finished dosage manufacturing capabilities, contributing an additional 10 billion dosage units annually.

About Haleos Labs Limited

SMS Lifesciences India Limited was incorporated originally as 'Potluri Real Estate Private Limited' on May 31, 2006.
The Company's name was changed to 'Potluri Packaging Industries Private Limited' on 6 November, 2013 and again changed to 'SMS Lifesciences India Private Limited on 4 August, 2014 to undertake the activities related pharma sector.
The Company became a wholly owned subsidiary Company of SMS Pharmaceuticals Limited w.e.f. 01.04.2016 and subsequently got converted into a Public Limited w.e.f. 22 June, 2016. The Company is engaged in the business of manufacturing and export of Active Pharma Ingredients(APIs) and their intermediates.
The Company is having manufacturing facilities at Kazipally and Jeedimetla, Hyderabad with an installed capacity of 65 KL. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having products spread across an array of therapeutic segments.

FAQs for the comparison of Granules India Ltd and Haleos Labs Limited

Which company has a larger market capitalization, Granules India Ltd or Haleos Labs Limited?

Market cap of Granules India Ltd is 17,327 Cr while Market cap of Haleos Labs Limited is 445 Cr

What are the key factors driving the stock performance of Granules India Ltd and Haleos Labs Limited?

The stock performance of Granules India Ltd and Haleos Labs Limited is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Granules India Ltd and Haleos Labs Limited?

As of May 3, 2026, the Granules India Ltd stock price is INR ₹699.25. On the other hand, Haleos Labs Limited stock price is INR ₹1474.9.

How do dividend payouts of Granules India Ltd and Haleos Labs Limited compare?

To compare the dividend payouts of Granules India Ltd and Haleos Labs Limited, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.